Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options

Blood

Volumn 114, Issue 27, 2009, Pages 5490-5498

  Stumpel, Dominique J P M ^a   Schneider, Pauline ^a   Van Roon, Eddy H J ^b   Boer, Judith M ^b   De Lorenzo, Paola ^c   Valsecchi, Maria G ^c   De Menezes, Renee X ^a,b   Pieters, Rob ^a   Stam, Ronald W ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; ZEBULARINE; CYTIDINE; DRUG DERIVATIVE; PYRIMIDIN 2 ONE BETA RIBOFURANOSIDE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HYBRIDIZATION; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT OUTCOME; CELL SURVIVAL; CHROMOSOME 11; CHROMOSOME 19; CHROMOSOME 4; CHROMOSOME 9; CLUSTER ANALYSIS; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA CELL LINE; PATHOLOGY; SURVIVAL; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 19; CHROMOSOMES, HUMAN, PAIR 4; CHROMOSOMES, HUMAN, PAIR 9; CLUSTER ANALYSIS; CPG ISLANDS; CYTIDINE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; JURKAT CELLS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 76249112147     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-227660     Document Type: Article

References (37)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-1043.
2. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240-250.
3. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia. 1996;10(2):372-377.
4. Jansen MW, Corral L, van der Velden VH, et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia. 2007;21(4):633-641.
5. Hess JL. Mechanisms of transformation by MLL. Crit Rev Eukaryot Gene Expr. 2004;14(4):235-254.
6. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359(9321):1909-1915.
7. Dou Y, Hess JL. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int J Hematol. 2008;87(1):10-18.
8. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30(1):41-47.
9. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002; 1(2):133-143.
10. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10(7):687-692.
11. Roman-Gomez J, Castillejo JA, Jimenez A, Barrios M, Heiniger A, Torres A. The role of DNA hypermethylation in the pathogenesis and prognosis of acute lymphoblastic leukemia. Leuk Lymphoma. Nov. 2003;44(11):1855-1864.
12. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-2054.
13. Stam RW, den Boer ML, Passier MM, et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia. 2006;20(2):264-271.
14. Stam RW, den Boer ML, Schneider P, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005; 106(7):2484-2490.
15. Pocock CF, Malone M, Booth M, et al. BCL-2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;11)(q21;q23) translocation. Br J Haematol. 1995;90(4):855-867.
16. Tang R, Faussat AM, Perrot JY, et al. A new acute lymphoblastic leukaemia cell line BEL-1 with t(4; 11) (q21; q23) chromosomal translocation and a unique aberrant p27 transcript. Br J Haematol. 2004;126(5):754-755.
17. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 1985;65(1):21-31.
18. Huang TH, Perry MR, Laux DE. Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet. 1999;8(3):459-470.
19. Yan PS, Wei SH, Huang TH. Differential methylation hybridization using CpG island arrays. Methods Mol Biol. 2002;200:87-100.
20. Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans. 2004;32(Pt 6):910-912.
21. Marquez VE, Barchi JJ, Jr., Kelley JA, et al. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):305-318.
22. Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood. 1990;76(11):2327-2336.
23. Zahurak M, Parmigiani G, Yu W, et al. Preprocessing Agilent microarray data. BMC Bioinformatics. 2007;8:142.
24. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Huber W, Carey V, Dudoit S, and Irizarry R, eds. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York, NY: Springer; 2005:397-420.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B. 1995;57(1):289-300.
26. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics. 2004;20(1):93-99.
27. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823-833.
28. Fraga MF, Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle. 2005;4(10):1377-1381.
29. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10(5):1107- 1117.
30. Nakamura T, Mori T, Tada S, et al. ALL-1 is a histone methyltransferase that assembles a super-complex of proteins involved in transcriptional regulation. Mol Cell. 2002;10(5):1119-1128.
31. Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007; 110(13):4445-4454.
32. Campo Dell'Orto M, Banelli B, Giarin E, et al. Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. Oncol Rep. 2007;18(2):417-423.
33. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007;39(4):457-466.
34. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res. 2005;11(16):5869-5877.
35. Dobrzycka KM, Kang K, Jiang S, et al. Disruption of scaffold attachment factor B1 leads to TBX2 up-regulation, lack of p19ARF induction, lack of senescence, and cell immortalization. Cancer Res. 2006;66(16):7859-7863.
36. Erfurth FE, Popovic R, Grembecka J, et al. MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci U S A. 2008;105(21):7517-7522.
37. Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14(5): 355-368.